combin amneal complet manag guid
ebitda compar rang
transact announc last year much delta chalk less way
synergi captur year still expect total synergi
said rang still reflect signific contribut new launch weight
therefor without risk though amneal side hous bring signific
exposur potenti higher-valu gener shots-on-go nonetheless believ
dynam reflect share ebitda mid-point guidanc
rang also bear mind net ebitda reiter
neutral rate lower pt owe primarili lower top-
latest color updat guidanc recal last octob amneal
manag team guid ebitda assert
delta rang new rang reflect revis assumpt relat
synergi captur current rang account cost save
year wherea prior rang reflect run-rat synergi one could
argu manag tacitli temper expect particularli consid
current rang reflect meaning contribut new gener launch name
back half also bear mind sale legaci
gener busi declin versu part relat
on-going suppli constraint associ adrenaclick said legaci ipxl
heavi exposur commodit oral solid
increas focu biosimilar though someth show stori
view amneal announc enter licens suppli agreement
biosimilar roch avastin bevacizumab note amneal exist
partnership adello biolog biosimilar filgrastim
color brand busi rytari solid brand invest horizon
sale impax brand busi sale
trajectori rytari continu favor sale growth excess
versu prescript product grew sequenti
versu grew versu per im manag suggest
invest brand busi like strategi endors given
legaci ipxl neurology-focus infrastructur continu
leverag given segment undoubtedli higher margin sourc cash flow
rytari commerci risk manufactur challeng competit gener
use formul expertis develop gener brand pharmaceut
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
guidanc pjc estim includ patent litig expens
consensu estim
compani report factset pjc estim
page
consensu
prior estim reflect previous publish illustr forma estim refer note detail
compani report factset pjc estim
page
million except per gener specialti amneal brand sale brand gener administr tax share amneal quarterli annual incom statement
million except ep
zomig brand sale
sale
sell gener administr
patent litig
incom loss tax
item net tax
expens revenu
sell gener administr
sell gener administr
ipxl began provid individu brand product sale earlier reflect pjc estim corepharma includ albenza emverm model reflect impact albenza gener competit start late
exclud cost relat remedi effort hayward ca manufactur facil
follow complet merger ameanl provid pro forma financi valu may reflect pjc estim
proprietari piper jaffray co may
page
million
net chang asset liabil
acquisit intang
stock option issuanc
proprietari piper jaffray co may
reflect cash-flow combin entiti
page
million
intang assets/oth estim reflect ipxl non-cash intang impair charg teva acquisit
reflect balanc sheet combin amneal entiti
proprietari piper jaffray co may
page
